Trials / Completed
CompletedNCT00983359
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Focal Therapy in the Treatment of Patients With 1-3 Brain Metastases
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Ohio State University Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase II trial is study how well stereotactic radiation therapy works in treating patients with brain metastases
Detailed description
OBJECTIVES: Primary * To determine the neurological death rate following the initiation of conformal stereotactic radiotherapy in patients with 1-3 brain metastases. Secondary * To determine the overall survival rate at 6 months. * To determine the progression-free survival rate or brain metastases recurrence rate at 6 months. * To determine the time to neurological death, time to systemic death, and Karnofsky decay time. * To determine the frequency and severity of adverse events associated with conformal stereotactic radiotherapy. OUTLINE: Patients undergo conformal stereotactic radiotherapy over 5 days to an area including 3 mm around the metastases or the surgical cavity. Patients may receive additional radiotherapy if symptomatic metastases emerge at different sites. After completion of study treatment, patients are followed up at 1 and 2 months and then every 3 months thereafter.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radiation Therapy | Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days. |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2009-09-24
- Last updated
- 2017-06-06
- Results posted
- 2016-06-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00983359. Inclusion in this directory is not an endorsement.